ViMRT
}  
 
Home   
< Docs   

 IV mutation literature information.


  Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility.
 PMID: 30201817       2018       Antimicrobial agents and chemotherapy
8Discussion: In the future, it is possible that the NA variants examined in our study may gain additional ""permissive"" mutations that improve their fitness, as was observed with the H275Y NA substitution in seasonal H1N1 viruses."
Introduction: The H273Y NA substitution in influenza B viruses occurs at the equivalent residue to that of the H275Y NA substitution in influenza A(H1N1) viruses, which was present in the oseltamivir-resistant influenza A(H1N1) viruses that spread globally in 2008/2009.


  An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
 PMID: 28087313       2017       Antiviral research
Introduction: In fact, the 2008-2009 seasonal influenza viruses with the H275Y NA mutation were completely resistant to the only orally bioavailable drug, oseltamivir.


  Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015-2016 season in Japan.
 PMID: 27714496       2017       Virus genes
Abstract: Overall, the prevalence of the H275Y A(H1N1)pdm09 viruses was 1.8 % (5/282).
Abstract: We report five cases of community- and hospital-acquired infections with oseltamivir- and peramivir-resistant A(H1N1)pdm09 viruses possessing the neuraminidase (NA) H275Y mutation during January-February 2016 in Japan.
Introduction: Five of A(H1N1)pdm09 isolates (5/282, 1.8 %) were found to possess the H275Y mutation.


  Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y.
 PMID: 28012921       2017       Antiviral research
Abstract: Evaluation of the in vivo antiviral activity showed that a single intravenous treatment of peramivir (10 mg/kg) prevented lethality in mice infected with wild-type H5N1 virus and also following infection with H5N1 virus with the H275Y mutation after a 5 day administration of peramivir (30 mg/kg).
Abstract: In H5N1 viruses containing the NA H275Y mutation, the antiviral activity of peramivir against the variant was lower than that against the wild-type.
Abstract: These results suggest that peramivir has therapeutic activity against HPAI viruses even if the virus harbors the NA H275Y mutation.


  Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014.
 PMID: 28128091       2017       Euro surveillance
Abstract: Day 149 when the patient had almost completed the second zanamivir treatment, mixes of the following resistance mutations were detected; H275Y(65.1%), I223R(9.2%), and E119G(89.6%), accompanied by additional mutations, showing a more complex viral population in the long-term treated patient.
Abstract: In a sample collected 15 days after the end of the first treatment with oseltamivir (Day 20 post-symptom onset), oseltamivir resistance was detected (mutation H275Y with 60.3% frequency by NGS).
Introduction: Among these, two well characterised mutations are the H275Y mutation which results in viruses with highly reduced inhibition by oseltamivir and the I223R mutation which results in reduced inhibition by both oseltamivir and zanamivir.

Browser Board

 Co-occurred Entities




   Filtrator